Print

Virdante Pharmaceuticals, Inc. Granted Key U.S. Patent Related to Sialic Switch Technology for Identifying Anti-Inflammatory Compounds  
1/6/2011 8:51:32 AM

(BUSINESS WIRE)--Virdante Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office has granted a key patent that supports the Company’s “Sialic Switch” technology for improving the anti-inflammatory activity of antibody-based drugs to treat autoimmune and inflammatory disorders. Virdante’s Sialic Switch technology is based on the principle of activating a novel anti-inflammatory pathway by specifically sialylating Fc-linked glycans of IgG antibodies.